Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, has relocated its corporate headquarters from Pennsylvania to the Company's facility in Winston-Salem.
"We are excited to move our corporate headquarters to Winston-Salem after having much of our research and development operations located here since 2004," said John L. Miclot, President and CEO. "This relocation allows us to focus our resources more efficiently on advancing our Neo-Urinary Conduit™ and Neo-Kidney Augment™ programs. The presence of a well-educated, high-quality workforce was also a factor in the decision to move our headquarters to Winston-Salem." Read more.